For a long time, Ascendis has been preparing for the approval of growth hormone Skytrofa, and the company can now execute launch and expansion plans.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Ascendis Pharma is chomping at the bit after securing a long-awaited approval for Transcon hGH, which will be marketed as Skytrofa. The company has already prepared launch plans to be initiated immediately.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.